Advanced treatments in non-clear renal cell carcinoma.
Identifieur interne : 000120 ( Main/Exploration ); précédent : 000119; suivant : 000121Advanced treatments in non-clear renal cell carcinoma.
Auteurs : El Mehdi Tazi [Maroc] ; Ismail Essadi ; Mohamed Fadl Tazi ; Youness Ahellal ; Hind M'Rabti ; Hassan ErrihaniSource :
- Urology journal [ 1735-546X ] ; 2011.
Descripteurs français
- KwdFr :
- MESH :
- thérapie : Néphrocarcinome, Tumeurs du rein.
- traitement médicamenteux : Néphrocarcinome, Tumeurs du rein.
- Humains, Prévision, Recherche biomédicale, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- MESH :
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- Biomedical Research, Forecasting, Humans, Molecular Targeted Therapy.
Abstract
PURPOSE
To focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma (RCC); papillary I and II, chromophobe, and collecting duct. The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them.
MATERIALS AND METHODS
On the basis of MEDLINE database searches, we assessed all aspects of targeted therapy in non-clear cell RCC between 2000 and 2010. Trials focusing on non-clear RCC or those that treated clear cell tumors along with significant numbers of non-clear subtypes will be discussed. The role of cytoreductive nephrectomy and the use of neoadjuvant and adjuvant targeted therapy will be reviewed. Lastly, areas of future research will be highlighted.
RESULTS
The majority of clinical trials testing novel targeted therapies have excluded non-clear subtypes, providing limited therapeutic options for patients with these diagnoses and their oncologists.
CONCLUSION
Patients presenting with advanced non-clear pathology should undergo a thorough metastatic evaluation and, if appropriate, surgical evaluation to determine if nephrectomy, lymphadenectomy, and/or metastectomy are warranted. Aggressive surgical extirpation is often recommended. Sunitinib also is adequately tolerated and oncologically active in subjects with non-clear histology.
PubMed: 21404194
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000697
- to stream PubMed, to step Curation: 000693
- to stream PubMed, to step Checkpoint: 000697
- to stream Main, to step Merge: 000120
- to stream Main, to step Curation: 000120
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Advanced treatments in non-clear renal cell carcinoma.</title><author><name sortKey="Tazi, El Mehdi" sort="Tazi, El Mehdi" uniqKey="Tazi E" first="El Mehdi" last="Tazi">El Mehdi Tazi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco. moulay.elmehdi@yahoo.fr</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Medical Oncology, National Institute of Oncology, Rabat</wicri:regionArea><placeName><settlement type="city">Rabat</settlement><region nuts="2">Rabat-Salé-Kénitra</region></placeName></affiliation></author><author><name sortKey="Essadi, Ismail" sort="Essadi, Ismail" uniqKey="Essadi I" first="Ismail" last="Essadi">Ismail Essadi</name></author><author><name sortKey="Tazi, Mohamed Fadl" sort="Tazi, Mohamed Fadl" uniqKey="Tazi M" first="Mohamed Fadl" last="Tazi">Mohamed Fadl Tazi</name></author><author><name sortKey="Ahellal, Youness" sort="Ahellal, Youness" uniqKey="Ahellal Y" first="Youness" last="Ahellal">Youness Ahellal</name></author><author><name sortKey="M Rabti, Hind" sort="M Rabti, Hind" uniqKey="M Rabti H" first="Hind" last="M'Rabti">Hind M'Rabti</name></author><author><name sortKey="Errihani, Hassan" sort="Errihani, Hassan" uniqKey="Errihani H" first="Hassan" last="Errihani">Hassan Errihani</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21404194</idno><idno type="pmid">21404194</idno><idno type="wicri:Area/PubMed/Corpus">000697</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000697</idno><idno type="wicri:Area/PubMed/Curation">000693</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000693</idno><idno type="wicri:Area/PubMed/Checkpoint">000697</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000697</idno><idno type="wicri:Area/Main/Merge">000120</idno><idno type="wicri:Area/Main/Curation">000120</idno><idno type="wicri:Area/Main/Exploration">000120</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Advanced treatments in non-clear renal cell carcinoma.</title><author><name sortKey="Tazi, El Mehdi" sort="Tazi, El Mehdi" uniqKey="Tazi E" first="El Mehdi" last="Tazi">El Mehdi Tazi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco. moulay.elmehdi@yahoo.fr</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Medical Oncology, National Institute of Oncology, Rabat</wicri:regionArea><placeName><settlement type="city">Rabat</settlement><region nuts="2">Rabat-Salé-Kénitra</region></placeName></affiliation></author><author><name sortKey="Essadi, Ismail" sort="Essadi, Ismail" uniqKey="Essadi I" first="Ismail" last="Essadi">Ismail Essadi</name></author><author><name sortKey="Tazi, Mohamed Fadl" sort="Tazi, Mohamed Fadl" uniqKey="Tazi M" first="Mohamed Fadl" last="Tazi">Mohamed Fadl Tazi</name></author><author><name sortKey="Ahellal, Youness" sort="Ahellal, Youness" uniqKey="Ahellal Y" first="Youness" last="Ahellal">Youness Ahellal</name></author><author><name sortKey="M Rabti, Hind" sort="M Rabti, Hind" uniqKey="M Rabti H" first="Hind" last="M'Rabti">Hind M'Rabti</name></author><author><name sortKey="Errihani, Hassan" sort="Errihani, Hassan" uniqKey="Errihani H" first="Hassan" last="Errihani">Hassan Errihani</name></author></analytic><series><title level="j">Urology journal</title><idno type="eISSN">1735-546X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biomedical Research (MeSH)</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (therapy)</term><term>Forecasting (MeSH)</term><term>Humans (MeSH)</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (therapy)</term><term>Molecular Targeted Therapy (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Humains (MeSH)</term><term>Néphrocarcinome (thérapie)</term><term>Néphrocarcinome (traitement médicamenteux)</term><term>Prévision (MeSH)</term><term>Recherche biomédicale (MeSH)</term><term>Thérapie moléculaire ciblée (MeSH)</term><term>Tumeurs du rein (thérapie)</term><term>Tumeurs du rein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Biomedical Research</term><term>Forecasting</term><term>Humans</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Prévision</term><term>Recherche biomédicale</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>To focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma (RCC); papillary I and II, chromophobe, and collecting duct. The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>On the basis of MEDLINE database searches, we assessed all aspects of targeted therapy in non-clear cell RCC between 2000 and 2010. Trials focusing on non-clear RCC or those that treated clear cell tumors along with significant numbers of non-clear subtypes will be discussed. The role of cytoreductive nephrectomy and the use of neoadjuvant and adjuvant targeted therapy will be reviewed. Lastly, areas of future research will be highlighted.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The majority of clinical trials testing novel targeted therapies have excluded non-clear subtypes, providing limited therapeutic options for patients with these diagnoses and their oncologists.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Patients presenting with advanced non-clear pathology should undergo a thorough metastatic evaluation and, if appropriate, surgical evaluation to determine if nephrectomy, lymphadenectomy, and/or metastectomy are warranted. Aggressive surgical extirpation is often recommended. Sunitinib also is adequately tolerated and oncologically active in subjects with non-clear histology.</p></div></front></TEI><affiliations><list><country><li>Maroc</li></country><region><li>Rabat-Salé-Kénitra</li></region><settlement><li>Rabat</li></settlement></list><tree><noCountry><name sortKey="Ahellal, Youness" sort="Ahellal, Youness" uniqKey="Ahellal Y" first="Youness" last="Ahellal">Youness Ahellal</name><name sortKey="Errihani, Hassan" sort="Errihani, Hassan" uniqKey="Errihani H" first="Hassan" last="Errihani">Hassan Errihani</name><name sortKey="Essadi, Ismail" sort="Essadi, Ismail" uniqKey="Essadi I" first="Ismail" last="Essadi">Ismail Essadi</name><name sortKey="M Rabti, Hind" sort="M Rabti, Hind" uniqKey="M Rabti H" first="Hind" last="M'Rabti">Hind M'Rabti</name><name sortKey="Tazi, Mohamed Fadl" sort="Tazi, Mohamed Fadl" uniqKey="Tazi M" first="Mohamed Fadl" last="Tazi">Mohamed Fadl Tazi</name></noCountry><country name="Maroc"><region name="Rabat-Salé-Kénitra"><name sortKey="Tazi, El Mehdi" sort="Tazi, El Mehdi" uniqKey="Tazi E" first="El Mehdi" last="Tazi">El Mehdi Tazi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/MaghrebDataLibMedV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000120 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000120 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= MaghrebDataLibMedV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21404194
|texte= Advanced treatments in non-clear renal cell carcinoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21404194" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MaghrebDataLibMedV2
| This area was generated with Dilib version V0.6.38. |  |